JWH-372
{{Short description|Chemical compound}}
{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = naphthalen-1-yl-[1-pentyl-5-[2-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
| image = JWH-372.svg
| width =
| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA = Schedule II
| legal_DE =
| legal_UK = Class B
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct}}
| CAS_number = 914458-28-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII =
| ATC_prefix =
| ATC_suffix =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL =
| PubChem = 44418325
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 23277903
| C=27 | H=24 | F=3 | N=1 | O=1
| smiles = CCCCCN1C=C(C=C1C2=CC=CC=C2C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H24F3NO/c1-2-3-8-16-31-18-20(17-25(31)23-13-6-7-15-24(23)27(28,29)30)26(32)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CYPUIQJYGVOHMM-UHFFFAOYSA-N
}}
JWH-372 (naphthalen-1-yl-[1-pentyl-5-[2-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as a potent and selective agonist of the CB2 receptor.
JWH-372 binds approximately 9 times stronger to the CB2 receptor (Ki = 8.2 ± 0.2nM) than the CB1 receptor (Ki = 77 ± 2nM). The selectivity of JWH-372 for the CB2 receptor is likely due to the electron-withdrawing character of the trifluoromethyl group rather than steric effects, as the o-methyl compound JWH-370 was only mildly selective for the CB2 receptor (CB1 Ki = 5.6 ± 0.4nM, CB2 Ki = 4.0 ± 0.5nM). {{cite journal | vauthors = Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR | title = 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors | journal = Bioorganic & Medicinal Chemistry Letters | volume = 16 | issue = 20 | pages = 5432–5 | date = October 2006 | pmid = 16889960 | doi = 10.1016/j.bmcl.2006.07.051 }}
Legality
In the United States JWH-372 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-372.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}{{cite web |title=The 2020 Florida Statutes |url=http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html |website=www.leg.state.fl.us |access-date=20 August 2021}}{{cite web |title=Arizona Revised Statutes Title 13. Criminal Code § 13-3401 |url=https://www.azleg.gov/ars/13/03401.htm |website=www.azleg.gov |access-date=20 August 2021}}{{cite web |title=California Code, Health and Safety Code - HSC § 11357.5 |url=https://codes.findlaw.com/ca/health-and-safety-code/hsc-sect-11357-5.html |website=Findlaw}}
In Canada, JWH-372 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.{{cn|date=August 2021}}
In the United Kingdom, JWH-372 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.{{cn|date=August 2021}}
See also
References
{{reflist}}
{{Cannabinoids}}
Category:CB1 receptor agonists
Category:CB2 receptor agonists
Category:Trifluoromethyl compounds
{{Cannabinoid-stub}}